R.M. Navari, S.E. Gray, A.C. Kerr. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. „J Support Oncol”. 9 (5), s. 188–195, 2011. DOI: 10.1016/j.suponc.2011.05.002. PMID: 22024310.
R.M. Navari, C.K. Nagy, S.E. Gray. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. „Support Care Cancer”. 21 (6), s. 1655–1663, 2013. DOI: 10.1007/s00520-012-1710-6. PMID: 23314603.
R.M. Navari, S.E. Gray, A.C. Kerr. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. „J Support Oncol”. 9 (5), s. 188–195, 2011. DOI: 10.1016/j.suponc.2011.05.002. PMID: 22024310.
R.M. Navari, C.K. Nagy, S.E. Gray. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. „Support Care Cancer”. 21 (6), s. 1655–1663, 2013. DOI: 10.1007/s00520-012-1710-6. PMID: 23314603.
urpl.gov.pl
bip.urpl.gov.pl
Urzędowy Wykaz Produktów Leczniczych [online], Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, 1 stycznia 2023 [dostęp 2024-01-18].